Source: WRAL, 7/1/20


The first of four experimental COVID-19 vaccines being tested by Pfizer and its German partner BioNTech showed encouraging results in very early testing of 45 people, the companies said Wednesday. Study volunteers given either a low or medium dose, in two shots about a month apart, had immune responses in the range expected to be protective, when compared to some COVID-19 survivors, according to the preliminary results. Side effects were typical for vaccines, mostly pain at the injection site and fever.

For more of this story, click here.